Subcutaneous Isatuximab Earns EU Approval in Multiple Myeloma – CancerNetwork: A New Era for Sarclisa Delivery
The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of a subcutaneous formulation of Sarclisa (isatuximab) for the treatment of multiple myeloma. This new delivery method, which can be administered via an on-body injector or manual injection, demonstrates comparable efficacy, safety, and pharmacokinetics to the existing intravenous infusion.
What is the significance of the CHMP recommendation for subcutaneous Sarclisa?
The positive opinion from the CHMP marks a major shift in how isatuximab is delivered to patients battling multiple myeloma (MM). According to a Sanofi press release dated March 27, 2026, the recommendation covers all currently approved indications for the intravenous (IV) formulation of Sarclisa within the European Union. This means patients across various stages of the disease may soon have a choice in how they receive their medication.
The primary significance lies in the diversification of administration. If the final approval is granted, Sarclisa will become the first anticancer treatment available through an on-body injector (OBI) in the EU. Furthermore, it will be the first multiple myeloma medicine to offer the dual flexibility of both an OBI and a manual subcutaneous injection.
For the oncology community, this is not merely a change in needle size or location. It represents a move toward reducing the time patients spend in clinical settings. Intravenous infusions typically require longer appointment times, specialized infusion chairs, and more intensive nursing supervision. A subcutaneous option streamlines this process, potentially increasing the throughput of oncology clinics and reducing the physical burden on the patient.
How does the on-body injector (OBI) change multiple myeloma treatment?
The introduction of the on-body injector (OBI) is a first for anticancer therapies in the EU. An OBI is a device that adheres to the skin and delivers the medication over a set period, removing the need for a healthcare provider to manually hold a syringe or manage a drip bag for the duration of the dose.
According to Sanofi, Sarclisa is the only anti-CD38 monoclonal antibody used in the treatment of multiple myeloma that provides the flexibility of both an OBI and manual injection. This dual-pathway approach allows providers to tailor the administration to the specific needs of the patient or the constraints of the healthcare facility.
“This positive CHMP opinion is a pivotal milestone in our mission to improve the treatment experience for multiple myeloma patients and providers,” says Olivier Nataf, Global Head of Oncology at Sanofi. “Our aim is to evolve the treatment experience by combining the clinically proven efficacy of Sarclisa with innovative subcutaneous delivery via an on-body injector.”
The impact of OBI technology can be broken down into three primary areas:
- Patient Comfort: Reduced time spent tethered to an IV pole and a decrease in the invasive nature of venous access.
- Provider Efficiency: Shorter administration windows allow oncology nurses and physicians to manage more patients effectively.
- Clinical Flexibility: The ability to switch between manual injection and OBI based on patient preference or clinical stability.
Comparing subcutaneous and intravenous isatuximab: What the data shows
A critical component of the CHMP’s positive opinion was the evidence regarding the comparability of the subcutaneous (SC) formulation to the intravenous (IV) version. For a new delivery method to be approved, it must prove that it does not compromise the drug’s ability to fight the cancer.
The recommendation was based on positive results showing that Sarclisa regimens administered subcutaneously maintained comparable efficacy, pharmacokinetics, and safety profiles when compared to the traditional IV infusion. Pharmacokinetics refers to how the body absorbs, distributes, metabolizes, and excretes the drug; the fact that these remain comparable suggests that the subcutaneous route delivers the isatuximab to the bloodstream in a manner that mirrors the IV route’s effectiveness.
| Feature | Intravenous (IV) Formulation | Subcutaneous (SC) Formulation |
|---|---|---|
| Administration Method | Infusion via vein | On-body injector (OBI) or Manual Injection |
| Clinical Efficacy | Established standard | Comparable to IV |
| Safety Profile | Established standard | Comparable to IV |
| Pharmacokinetics | Direct systemic entry | Comparable to IV |
| Clinic Time | Generally longer | Potentially shorter |
Why flexibility in administration matters for oncology patients
Multiple myeloma is often a chronic condition requiring long-term, repeated dosing. The cumulative “treatment burden”—the total time, stress, and physical toll of receiving care—can significantly impact a patient’s quality of life. By offering a subcutaneous option, the medical community can address several systemic pain points.
Reducing “Infusion Fatigue”
Patients receiving IV therapy often face “infusion fatigue,” where the repeated need for venous access leads to scarred veins or the necessity of implanted ports. Subcutaneous injections bypass the venous system, utilizing the fatty tissue under the skin, which is generally less traumatic for the patient over many cycles of treatment.
Expanding Access to Care
The ability to administer medication via manual injection or an OBI may allow for more flexible scheduling. While the specific protocols for Sarclisa SC will be determined by final EU approval and local health guidelines, the shift away from mandatory IV infrastructure can potentially open doors for different care settings, reducing the reliance on large hospital infusion centers.
The Role of Anti-CD38 Monoclonal Antibodies
Isatuximab belongs to a class of drugs called anti-CD38 monoclonal antibodies. These are designed to target the CD38 protein, which is highly expressed on the surface of myeloma cells. By binding to this protein, the drug triggers the destruction of the cancerous plasma cells. The approval of the SC formulation ensures that the potent mechanism of isatuximab is now available in a more versatile package.
Addressing common misconceptions about subcutaneous delivery
When a drug moves from IV to SC, some patients and providers worry that the medication is “weaker” or that the body does not absorb it as well. However, the CHMP’s recommendation specifically addresses this through the verification of pharmacokinetics. In the case of Sarclisa, the data confirms that the subcutaneous route is not a “compromise” but an alternative that maintains the same therapeutic impact.
Another misconception is that OBI devices are only for home use. While OBI technology facilitates easier administration, the initial rollout and oversight of these devices typically remain under the strict guidance of oncology professionals to ensure proper placement and monitoring for any adverse reactions.
It is also important to distinguish between “manual injection” and “on-body injection.” Manual injection is a traditional shot delivered by a clinician. The OBI is a device that stays on the patient. The fact that Sarclisa offers both provides a level of redundancy and choice that is currently unique among anti-CD38 therapies for multiple myeloma in the EU.
The path toward final EU approval
The CHMP’s positive opinion is the primary scientific hurdle in the European regulatory process. The committee’s role is to evaluate the data and provide a recommendation to the European Commission (EC). While the CHMP does not grant the final legal approval, the EC almost always follows the CHMP’s scientific guidance.
A final decision from the European Commission is expected in the coming months. Once approved, the subcutaneous formulation will be integrated into the approved indications for Sarclisa IV, allowing physicians to transition patients from IV to SC or start new patients on the SC route depending on the clinical scenario.
For those interested in the evolving landscape of oncology, this development is a clear indicator of a broader industry trend: the “subcutinization” of biologics. By transforming complex IV drugs into simpler injections, pharmaceutical companies are attempting to solve the logistical bottlenecks of modern cancer care.
Frequently Asked Questions
What is the difference between Sarclisa IV and Sarclisa SC?
Sarclisa IV is administered through a vein via infusion, which typically takes longer. Sarclisa SC is administered under the skin, either through a manual injection or an on-body injector (OBI), and has been shown to have comparable efficacy and safety to the IV version.
What is an on-body injector (OBI)?
An OBI is a device that adheres to the skin and delivers medication automatically over a period of time. According to Sanofi, Sarclisa would be the first anticancer treatment administered via an OBI if approved in the EU.
Does the subcutaneous version of isatuximab work as well as the intravenous version?
Yes. The CHMP’s positive opinion was based on data demonstrating that the subcutaneous formulation has comparable efficacy, pharmacokinetics, and safety to the intravenous infusion.
Who is eligible for the subcutaneous formulation of Sarclisa?
The recommendation covers all currently approved indications for the Sarclisa intravenous formulation in the EU. Specific eligibility will be determined by prescribing physicians following final approval.
Is Sarclisa the only drug of its kind with this delivery flexibility?
According to the manufacturer, Sarclisa is the only anti-CD38 monoclonal antibody for multiple myeloma that offers the flexibility of both an on-body injector and manual injection in the EU.
